BioSpace News Archive

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762.

Berkeley Lights and IsoPlexis announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 41st annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 9th, 2023 at 10:30 AM Eastern Standard Time.

Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, will make a presentation to investors at the J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 3:45 p.m. Pacific time.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.

Everest Medicines announced that its licensing partner, Pfizer Inc. has received acceptance from the U.S. Food and Drug Administration for review a New Drug Application for etrasimod for individuals living with moderately-to-severely active ulcerative colitis.

The brain cancer, glioblastoma, is a fierce and formidable opponent. Its millions of victims include Senator John McCain, President Biden’s son, Beau, and famed film critic Gene Siskel, to name just a few.

Lupin Pharmaceuticals Inc. is voluntarily recalling four (4) lots of Quinapril Tablets to the patient (consumer/user) level due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 2:15PM Pacific Time.

Genentech today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab).